Base editing makes it to clinical trials.

"Trial organizers announced on 5 September that the first participant had been treated using immune cells with four base-edited genes, equipping the cells to better target and destroy tumours. The hope is that the approach can tame trial participants’ difficult-to-treat form of leukaemia and serve as a gateway to more complex edits in the future."

https://www.nature.com/articles/d41586-023-02836-7?utm_source=Nature+Briefing&utm_campaign=2e1b5e1000-briefing-dy-20230919&utm_medium=email&utm_term=0_c9dfd39373-2e1b5e1000-44356001